Medical devices intended for small patient populations can address important clinical needs while presenting particular challenges for evidence generation. Recruiting patients, obtaining suitable specimens and collecting sufficient clinical data may be difficult when the disease or condition is rare.
Two Medical Device Coordination Group (MDCG) guidance documents address these challenges: MDCG 2024-10 on the clinical evaluation of orphan medical devices under the MDR, and MDCG 2026-6 on clinical evidence for orphan in vitro diagnostic medical devices under the IVDR.
The publication of the latter on 3 November 2026 provides an opportunity to explore what “orphan” means for medical devices, how the two documents approach clinical evidence and where their scope differs.

At a glance
- The concept: orphan status combines an epidemiological criterion with insufficient available alternatives or an expected clinical benefit compared with alternatives or the state of the art.
- The threshold: the guidance uses a criterion of no more than 12,000 individuals in the EU per year, with specific considerations for orphan populations and subpopulations.
- The documents: MDCG 2024-10 addresses clinical evaluation under the MDR; MDCG 2026-6 addresses clinical evidence for orphan IVDs.
- The evidence: justified limitations in pre-market clinical data or clinical performance data may be acceptable under the conditions described in the guidance.
- The distinction: orphan status does not remove the applicable regulatory requirements or confer market exclusivity.
What are orphan medical devices?
For the purposes of MDCG 2024-10, an orphan device is a medical device or accessory specifically intended to benefit patients in the treatment, diagnosis or prevention of a disease or condition that presents in no more than 12,000 individuals in the European Union per year.
The epidemiological criterion is accompanied by at least one of two further criteria:
- available alternatives for treatment, diagnosis or prevention are insufficient;
- the device is expected to provide a clinical benefit compared with available alternatives or the state of the art.
MDCG 2026-6 takes a similar approach for IVDs, referring to tests intended for a disease, condition or circumstance that presents in no more than 12,000 individuals in the EU per year, together with insufficient alternatives or an expected clinical benefit.
A small market or low sales volume does not, by itself, establish orphan status. The criteria concern the relevant population, intended purpose and clinical context.
The guidance describes justification of the epidemiological criterion through incidence estimates for the EU population. It acknowledges that data may be limited and considers scientific sources, public health statistics and appropriately justified extrapolations, alongside specific considerations for rare diseases.
For IVDs, MDCG 2026-6 expressly distinguishes the epidemiological threshold from the number of tests performed. An orphan IVD may be used to test more people than the affected population, for example when identifying affected individuals, or may be used repeatedly in the same patient.
The threshold therefore does not represent an annual limit of 12,000 tests.
Orphan device or orphan indication?
Both documents also recognise clinically valid orphan subpopulations within more common diseases or conditions.
This does not mean that a larger population can simply be divided to meet the numerical threshold. The existence of the subpopulation and the relevance of the intended use require scientific justification.
A device may also have an orphan indication alongside non-orphan indications. In such cases, the guidance principles may support the orphan indication where duly justified, without extending that approach automatically to the device’s other uses.
The distinction matters because evidence available for a larger population may not adequately address the specific characteristics of the orphan population. Both documents discuss the possible extrapolation of data, subject to its scientific relevance and justification.
These concepts should be distinguished from orphan medicinal product designation. The MDCG guidance documents define orphan status criteria for devices within their respective scope and clarify that this status does not confer market exclusivity.
The guidance indicates that a manufacturer claiming orphan status should provide a documented scientific justification based on epidemiological and device-related considerations. This justification is distinct from the evidence required for conformity assessment.
Orphan medical devices under the MDR
MDCG 2024-10, Clinical evaluation of orphan medical devices, was published in June 2024.
It addresses medical devices and accessories with orphan status or an orphan indication across the MDR risk classes, within the scope defined by the document.
The central issue is how to assess clinical evidence when generating additional pre-market data is particularly difficult. Limited patient numbers, vulnerable populations and practical or ethical constraints may affect the feasibility of clinical investigations.
The guidance describes circumstances in which limitations in the amount and quality of pre-market clinical data may be acceptable. This remains conditional on sufficient evidence to support conformity with the relevant general safety and performance requirements, an acceptable benefit-risk ratio and an expected clinical benefit.
The assessment also considers whether generating further pre-market clinical data within an acceptable timeframe is feasible and proportionate.
Non-clinical data may contribute to the overall assessment, but their relevance and quality remain important. The guidance does not establish a general exemption from clinical evidence requirements.
Post-market clinical follow-up (PMCF) has a central role in addressing accepted limitations through further clinical data collection.
The document also emphasises the importance of adequately informing users about the device’s orphan status, limitations in the available clinical data, and how to report incidents, complaints and other clinical experience to the manufacturer.
Its scope excludes custom-made devices, in-house devices, products without an intended medical purpose listed in MDR Annex XVI, and IVDs.
Orphan IVDs under the IVDR
MDCG 2026-6, Clinical evidence for orphan in vitro diagnostic medical devices, addresses orphan IVDs and orphan indications across the IVDR risk classes.
For these devices, a particular challenge is obtaining sufficient suitable specimens from the relevant population. The difficulty may concern specific clinical performance parameters rather than every aspect of the evaluation.
The general framework of performance evaluation continues to apply. It encompasses scientific validity, analytical performance and clinical performance.
The guidance uses non-clinical data to mean relevant data that do not meet the IVDR definition of clinical performance data. In this context, the term includes scientific validity and analytical performance data.
Such data can contribute to the assessment of safety, performance and the benefit-risk profile, provided their relevance to the orphan IVD is justified.
Limitations in pre-market clinical performance data may be acceptable under the conditions described in the document. Sufficient clinical evidence is still needed to support the expected clinical benefit and demonstrate that the device performs as intended with an acceptable level of safety.
The guidance also makes clear that limitations should relate to parameters for which generating data is particularly challenging. For example, where negative specimens are not scarce, sufficient testing remains relevant to establishing specificity.
Post-market performance follow-up (PMPF) and post-market surveillance (PMS) are particularly important for addressing remaining limitations and continuing to assess performance and safety.
MDCG 2026-6 also emphasises the importance of adequately informing users about the device’s orphan status, limitations in pre-market clinical performance data, and how to report incidents, complaints and other clinical experience to the manufacturer.
This information may be provided through labelling, instructions for use, the summary of safety and performance where applicable, or other accompanying documentation.
MDR and IVDR: similarities and differences
| Aspect | MDR | IVDR |
|---|---|---|
| Guidance | MDCG 2024-10 | MDCG 2026-6 |
| Devices covered | Medical devices and accessories with orphan status or an orphan indication, within the document’s scope | IVDs with orphan status or an orphan indication |
| Main focus | Clinical evaluation | Clinical evidence and performance evaluation, with particular attention to clinical performance |
| Evidence limitations addressed | Limitations in pre-market clinical data | Limitations in pre-market clinical performance data |
| Post-market follow-up | PMCF, within the wider PMS framework | PMPF, within the wider PMS framework |
| In-house devices | Excluded from the guidance’s scope | Specified general principles are relevant to in-house orphan IVDs under Article 5(5) IVDR |
| Expert panels | Voluntary advice under the scenarios described in the guidance | Voluntary advice under the scenarios described in the guidance; procedural provisions do not apply to in-house IVDs |
The shared approach is to consider the challenges of small populations while maintaining the need for sufficient evidence. The differences reflect the devices concerned and the respective regulatory frameworks.
What is different for in-house IVDs?
MDCG 2026-6 expressly addresses EU health institutions that manufacture and use orphan IVDs in-house under Article 5(5) IVDR.
When the conditions of that provision are met, these devices are exempt from most IVDR requirements, including certification. They nevertheless remain subject to the relevant general safety and performance requirements in Annex I.
The guidance explains that the general principles outlined in sections 4 to 9 and Annexes 3 and 4 are also relevant to these institutions, within the scope and conditions described in the document.
These principles concern, among other matters, justification of orphan status, evidence generation, the role of non-clinical data and the possible acceptability of justified limitations in clinical performance data.
For in-house orphan IVDs, the guidance indicates that claims of orphan status should be adequately substantiated and documented.
The exemption under Article 5(5) also does not exclude the possible application of IVDR provisions on performance studies, where relevant.
However, this does not extend the entire document to in-house IVDs. Procedural statements concerning notified bodies, certification, CE marking, reports and expert panels do not apply to orphan IVDs manufactured by health institutions under this framework.
The distinction is therefore between the relevance of scientific principles for demonstrating safety and performance and the procedures applicable to devices undergoing conformity assessment for CE marking.
The role of notified bodies and expert panels
Where a notified body is involved, the guidance describes its assessment of the justification for orphan status, the available evidence and any proposed acceptance of pre-market data limitations.
Post-market data collection is part of this assessment. Both documents discuss certificates with specific conditions or provisions, including defined follow-up activities to generate further data.
Expert panels may provide advice on orphan status and the clinical data or clinical performance data needed for evaluation, under the scenarios described in each document.
This consultation is voluntary and remains distinct from the clinical evaluation consultation procedure under the MDR and the performance evaluation consultation procedure under the IVDR.
Advice on orphan status does not replace conformity assessment or establish, by itself, that a device meets the applicable requirements.
Why these guidance documents matter
Orphan devices illustrate a recurring challenge: an important clinical need may concern a population too small to support conventional approaches to evidence generation within a reasonable timeframe.
The two MDCG documents describe how those circumstances can be considered while retaining the need to demonstrate conformity with the relevant requirements.
For manufacturers and notified bodies, the practical significance lies particularly in justifying orphan status, identifying limitations in pre-market evidence and planning the follow-up activities needed to address them.
Their significance therefore extends beyond the initial assessment. Accepted limitations in pre-market data are connected to continued evidence generation, reassessment of the benefit-risk profile and transparency about what is known and what remains uncertain.
The guidance supports a lifecycle approach to clinical evidence for orphan devices. It does not make orphan status an automatic exemption from safety, performance or conformity assessment requirements.
Official sources
- MDCG 2024-10 — Clinical evaluation of orphan medical devices
- MDCG 2026-6 — Clinical evidence for orphan in vitro diagnostic medical devices
Stay informed with MDN – Medical Device News
MDN is a free weekly newsletter dedicated to regulatory updates on medical devices and IVDs, based on official and institutional sources.
Subscribers receive it by email every Monday, one week before publication on the website.
Subscribe to MDN – Medical Device News.
Did you find this insight useful?
If you found this insight useful, you can share it with other professionals in the sector.
More articles
Informational note
This article is for informational purposes only and does not constitute regulatory, legal, technical or professional advice. For applicable requirements and procedures, please refer to the official texts and current documentation issued by the competent authorities.





